IDXX Earnings Prediction
The chart below shows how IDXX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IDXX sees a +1.19% change in stock price 10 days leading up to the earnings, and a +5.42% change 10 days following the report. On the earnings day itself, the stock moves by -0.26%. This data can give you a slight idea of what to expect for the next quarter's release.
IDXX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
975.54M
6.56%
-2.79%
Gross Margin
61.10%
2.09%
-0.97%
Operating Margin
31.15%
3.59%
18.49%
Net Margin
23.87%
2.98%
17.82%
EPS
2.80
10.67%
14.75%
No Data Available
IDXX Earnings Analysis
Idexx Laboratories Inc Corporation (IDXX.O) Earnings Conference Call
Positive
Organic Revenue Growth: 1. Solid Organic Revenue Growth: IDEXX reported a 6% organic revenue growth in Q3 2024, driven by a 7% increase in CAG diagnostic recurring revenues and a 13% growth in the water business.
EPS Growth Achievement: 2. Strong EPS Performance: The company achieved an EPS of $2.80 in Q3, reflecting an 11% increase as reported and a 12% increase on a comparable basis.
Customer Loyalty Success: 3. High Customer Retention Rates: IDEXX maintained a customer retention rate exceeding 97%, showcasing strong customer loyalty and satisfaction.
Premium Instrument Growth: 4. Increased Premium Instrument Install Base: The global premium instrument install base grew by 10% year-on-year, supported by strong demand for IDEXX technology.
Strong Free Cash Flow: 5. Robust Free Cash Flow: IDEXX generated $192 million in free cash flow in Q3, with a trailing twelve-month net income to free cash flow conversion ratio of 91%.
Negative
CAG Instrument Revenue Decline: 1. Decline in CAG Instrument Revenue: CAG instrument revenue decreased 9% organically, attributed to record prior year placement levels and a focus on new order generation for the IDEXX In View Analyzer, impacting near-term revenues.
Organic Revenue Guidance Reduction: 2. Negative Impact from Macro Pressures: The company updated its full-year organic revenue growth guidance to reflect a reduction of 1% to 1.5% due to ongoing US macro and sector pressures, particularly affecting clinical visit growth.
Declining Clinical Visit Growth: 3. Weak Same Store Clinical Visit Growth: Same store clinical visit growth declined by 2.1% in Q3, with a more significant 3.4% drop in discretionary wellness visits, indicating a challenging environment for veterinary services.
Revenue Outlook Reduction: 4. Reduced Full-Year Revenue Outlook: The updated full-year reported revenue outlook is $3.865 billion to $3.890 billion, a reduction of $38 million at midpoint, reflecting the impact of macroeconomic conditions and severe weather events.
Reference Lab Pricing Pressure: 5. Pressure on Reference Lab Pricing: Reference lab growth was moderated by new customer agreements, which impacted price realization, indicating potential headwinds for revenue growth in the coming quarters.
IDXX FAQs
How does IDXX typically perform around its earnings report dates?
Is IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IDXX Earning Call Sentiment
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
IDXX.O
-1.79%Positive
The earnings call presents a mixed picture: strong financial metrics with 11% EPS growth and a 9% increase in gross profit, but lower revenue guidance and moderated price gains. The Q&A reveals concerns about clinic demand and pricing headwinds, yet emphasizes innovation and strategic growth. Share repurchases positively impact shareholder returns. Overall, the sentiment is balanced, with positive financial performance but tempered by cautious guidance and external pressures.